Survival in patients with CLL according to characteristics
| Variable . | No. patients . | Dead (%) . | Median survival (mo) . | 2-y survival (%) (95% CI) . | 3-y survival (%) (95% CI) . | P value . |
|---|---|---|---|---|---|---|
| Age | ||||||
| ≤60 y | 92 | 16 (17) | NR | 87 (79-95) | 70 (60-80) | .065 |
| >60 y | 85 | 26 (31) | 37 | 75 (67-83) | 64 (51-77) | |
| Rai stage | ||||||
| 0 | 44 | 2 (5) | NR | 95 (89-100) | 95 (89-100) | |
| I | 78 | 11 (14) | NR | 93 (87-99) | 80 (67-93) | |
| II | 24 | 11 (46) | 30 | 60 (40-80) | 46 (22-70) | <0.00001 |
| III | 8 | 4 (50) | 25 | 63 (29-97) | 47 (11-83) | |
| IV | 23 | 14 (61) | 19 | 43 (22-64) | 37 (15-59) | |
| β2-microglobulin | ||||||
| <2 | 33 | 1 (3) | NR | 96 (89-100) | 96 (89-100) | |
| 2 to <3 | 55 | 6 (11) | NR | 93 (86-100) | 86 (75-96) | |
| ≥3 to <4 | 35 | 10 (29) | NR | 78 (63-93) | 63 (43-83) | <0.00001 |
| ≥4 | 30 | 19 (63) | 18 | 43 (25-61) | 25 (1-49) | |
| Prior therapy | ||||||
| No | 102 | 8 (8) | NR | 94 (89-97) | 92 (86-98) | <0.00001 |
| Yes | 75 | 34 (45) | 33 | 63 (52-74) | 46 (32-60) | |
| LDH | ||||||
| Normal | 125 | 20 (16) | NR | 86 (80-92) | 80 (71-89) | <0.00001 |
| Elevated | 34 | 20 (59) | 26 | 54 (36-72) | 33 (13-53) | |
| Serum IL-10 | ||||||
| ≤10 pg/mL | 105 | 12 (11) | NR | 92 (87-97) | 5 (77-93) | <0.00001 |
| >10 pg/mL | 54 | 26 (48) | 32 | 62 (49-75) | 45 (29-61) | |
| Serum IL-6 | ||||||
| ≤4.30 pg/mL | 115 | 18 (16) | NR | 90 (84-96) | 81 (72-91) | 0.0004 |
| >4.30 pg/mL | 36 | 16 (44) | NR | 61 (45-77) | 51 (33-69) | |
| IL-6 + IL-10 | ||||||
| Neither elevated | 75 | 6 (8) | NR | 96 (91-100) | 89 (81-97) | <0.00001 |
| One elevated | 42 | 14 (33) | 36 | 75 (62-88) | 50 (33-67) | |
| Both elevated | 16 | 10 (63) | 19 | 50 (25-75) | 27 (0-54) |
| Variable . | No. patients . | Dead (%) . | Median survival (mo) . | 2-y survival (%) (95% CI) . | 3-y survival (%) (95% CI) . | P value . |
|---|---|---|---|---|---|---|
| Age | ||||||
| ≤60 y | 92 | 16 (17) | NR | 87 (79-95) | 70 (60-80) | .065 |
| >60 y | 85 | 26 (31) | 37 | 75 (67-83) | 64 (51-77) | |
| Rai stage | ||||||
| 0 | 44 | 2 (5) | NR | 95 (89-100) | 95 (89-100) | |
| I | 78 | 11 (14) | NR | 93 (87-99) | 80 (67-93) | |
| II | 24 | 11 (46) | 30 | 60 (40-80) | 46 (22-70) | <0.00001 |
| III | 8 | 4 (50) | 25 | 63 (29-97) | 47 (11-83) | |
| IV | 23 | 14 (61) | 19 | 43 (22-64) | 37 (15-59) | |
| β2-microglobulin | ||||||
| <2 | 33 | 1 (3) | NR | 96 (89-100) | 96 (89-100) | |
| 2 to <3 | 55 | 6 (11) | NR | 93 (86-100) | 86 (75-96) | |
| ≥3 to <4 | 35 | 10 (29) | NR | 78 (63-93) | 63 (43-83) | <0.00001 |
| ≥4 | 30 | 19 (63) | 18 | 43 (25-61) | 25 (1-49) | |
| Prior therapy | ||||||
| No | 102 | 8 (8) | NR | 94 (89-97) | 92 (86-98) | <0.00001 |
| Yes | 75 | 34 (45) | 33 | 63 (52-74) | 46 (32-60) | |
| LDH | ||||||
| Normal | 125 | 20 (16) | NR | 86 (80-92) | 80 (71-89) | <0.00001 |
| Elevated | 34 | 20 (59) | 26 | 54 (36-72) | 33 (13-53) | |
| Serum IL-10 | ||||||
| ≤10 pg/mL | 105 | 12 (11) | NR | 92 (87-97) | 5 (77-93) | <0.00001 |
| >10 pg/mL | 54 | 26 (48) | 32 | 62 (49-75) | 45 (29-61) | |
| Serum IL-6 | ||||||
| ≤4.30 pg/mL | 115 | 18 (16) | NR | 90 (84-96) | 81 (72-91) | 0.0004 |
| >4.30 pg/mL | 36 | 16 (44) | NR | 61 (45-77) | 51 (33-69) | |
| IL-6 + IL-10 | ||||||
| Neither elevated | 75 | 6 (8) | NR | 96 (91-100) | 89 (81-97) | <0.00001 |
| One elevated | 42 | 14 (33) | 36 | 75 (62-88) | 50 (33-67) | |
| Both elevated | 16 | 10 (63) | 19 | 50 (25-75) | 27 (0-54) |
CLL indicates chronic lymphocytic leukemia; CI, confidence interval; NR, not reached; LDH, lactate dehydrogenase; IL-10, interleukin 10; IL-6, interleukin 6.